Boston Scientific to acquire Axonics for $3.7B

Boston Scientific announced a definitive agreement to acquire Axonics, a medical technology company focused on devices for urinary and bowel dysfunction, for $71 per share, representing an equity value of approximately $3.7 billion.

“Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Axonics, Inc., a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.”news.bostonscientific.com

• 1 source
• news.bostonscientific.comBoston Scientific Announces Agreement to Acquire Axonics, Inc.Jan 8, 2024

Summarized from public sources; check the original articles before acting on it.